RecruitingNCT04300257
Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care
Sponsor
Kantonsspital Winterthur KSW
Enrollment
600 participants
Start Date
Oct 19, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
The primary significance of this project is to perform a detailed analysis to assess the diagnostics, treatment and follow-up care, to develop a prediction model for future patient selection regarding various diagnostic and treatment procedures.
Eligibility
Plain Language Summary
Simplified for easier understanding
This is a data registry study from the Swiss Sarcoma Network. Researchers are collecting health information from bone and soft tissue tumor patients to build a model that predicts which patients benefit most from specific treatments.
**You may be eligible if...**
- You have been diagnosed with a malignant (cancerous), intermediate-grade, or selected benign bone or soft tissue tumor, as classified by the Swiss Sarcoma Network
- You are any age, male or female
**You may NOT be eligible if...**
- You have formally objected to your personal health data being used for research purposes
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04300257
Related Trials
Combination Immunotherapy Targeting Sarcomas
NCT044332211 location
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
NCT011093945 locations
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
NCT023907521 location
Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)
NCT061036691 location
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
NCT0678917210 locations